Video Series

Angela Lamb examined the real-world challenges of capturing patient-reported outcomes in clinical practice, noting that while standardized pre-visit assessments and long-term tracking of quality of life and itch scores are theoretically ideal, implementation barriers such as varying electronic medical record (EMR) systems and competing clinical demands make consistent adoption difficult outside of clinical trial settings.

Explore evolving biomarker testing for rare neuroendocrine carcinomas—NGS, MSI/TMB, and emerging DLL3 targets guiding new trials.

In this episode, 'Screening, Risk Stratification, and the Multidisciplinary Care Model for MASH,' the hepatologist Nadege Gunn, MD explores the following questions: 1. How would you characterize the urgency of MASH as a public health problem for a primary care physician who may see the early signs? 2. In an ideal world, what does the multidisciplinary care model for a MASH patient with significant obesity look like? How far is current clinical practice from that ideal, and where do the current gaps exist?

Clinicians weigh generics, formularies and breakthrough psychiatry meds, from clozapine to esketamine, to treat resistance while managing costs, risks.

Welcome back to another AJMC Insights series. In this episode titled, 'MASH in Focus: How Patient Awareness, Clinical Empowerment, and Research Have Transformed the Field,' Nadege Gunn, MD led the conversation about the following questions: 1. As a hepatologist, how has the MASH patient population changed over the last decade? 2. Do you feel the broader medical community has kept pace with that shift? 3. How much of your current liver disease caseload would you attribute to metabolic and obesity-driven disease versus other etiologies?

Clinicians unpack why meds fail—patient fit, side effects, and adherence—and share practical ways to boost understanding and remission.

In this AJMC Insights episode, Angela Lamb discusses how clinicians diagnose and assess atopic dermatitis using clinical scoring tools and patient-centered goal setting, emphasizing the importance of evaluating both disease severity and patient-reported symptoms to guide individualized treatment decisions.

Experts explain evolving biomarker testing for rare neuroendocrine carcinomas, from NCCN gaps to DLL3 and NGS, guiding trials and treatment.

Learn how aggressive neuroendocrine carcinoma disrupts daily life—and why rapid treatment, strong caregiver support, and navigation resources matter.

Clinicians navigate insurance formularies, prior authorizations, and step therapy—using 14‑day check-ins and PHQ‑9 data to win better meds.

Experts warn extrapulmonary neuroendocrine carcinomas are often missed; faster pathology, rapid referrals, and early treatment improve survival.

Rare neuroendocrine carcinomas outside the lung often go missed; expert pathology and rapid referrals enable earlier treatment and better outcomes.

How health systems break silos with multidisciplinary, patient-centered teams to improve CRM outcomes through coordinated, holistic care.

Clinicians weigh antipsychotic choices with patients, tracking labs and side effects, while navigating insurance and brand-vs-generic variability.

Experts reveal how stigma, misdiagnosis, and cost barriers delay depression, bipolar, and schizophrenia care—and what breaks the crisis cycle.

How combined therapies and proactive, team-based CRM care cut costs, streamline meds, and improve heart, kidney, and metabolic outcomes.

The panelists examined how the scarcity of mental health specialists creates a cascading effect on care capacity, where patients who do not respond to initial primary care treatment face an increasingly narrow pool of expert clinicians equipped to manage complex, refractory cases.

Learn how rare neuroendocrine cancers are diagnosed, why pathology and Ki-67 guide care, and how teams coordinate chemo, trials, support.

New factor XIa inhibitors cut recurrent non-cardioembolic stroke without extra bleeding—plus what milvexian and abilacimab trials reveal.

Experts unpack neuroendocrine carcinoma vs tumors, key pathology markers, and high-risk features shaping prognosis and treatment decisions.

Factor XIa blockers aim to prevent stroke-driving clots with less bleeding; explore leading phase 3 drugs and oral vs IV tradeoffs.

The expert dermatologist examined how patient-specific factors drive JAK inhibitor selection, with baricitinib favored for patients who prioritize an established long-term safety record, ritlecitinib preferred for adolescents aged 12 to 17 and patients with baseline dyslipidemia, and deuruxolitinib reserved for those seeking faster and more robust hair regrowth or who have not responded adequately to another JAK inhibitor.

Dr. Mostaghimi discussed the clinical trial data for deuruxolitinib, a JAK1/2 inhibitor dosed at 8 mg twice daily, which demonstrated a faster onset of action compared with baricitinib and ritlecitinib — achieving mid-30% Scalp Area and Hair Loss Tool (SALT) score less than 20 response rates at 24 weeks, approximately 3 months earlier than baricitinib at 36 weeks.

The panelist examined the pivotal trial design for baricitinib, which enrolled patients with severe AA — defined as a Scalp Area and Hair Loss Tool (SALT) score greater than 50 — and demonstrated that approximately 30% of patients achieved a SALT score below 20 at 36 weeks on the 4 mg dose, with the 2 mg dose performing substantially lower.

Arash Mostaghimi highlighted the scientific journey that led to Janus kinase (JAK) inhibitors becoming a treatment avenue for alopecia areata, beginning with a case report by Brett King in which a patient with psoriatic arthritis receiving tofacitinib experienced complete scalp hair regrowth despite also having AA.

The expert clinician examined the multidisciplinary approach to alopecia areata care, with the board-certified dermatologist serving as the central coordinator, supported by pediatricians and family practice providers for early recognition and timely referral, dermatopathologists for cases requiring biopsy, and specialists in endocrinology, rheumatology, and psychiatry or psychology for management of associated comorbidities and psychosocial needs.

The panelist discussed the SALT scoring system, which divides the scalp into four regions — the frontal parietal scalp, bilateral preauricular and postauricular scalp, and posterior scalp — and evaluates the percentage of hair loss in each area to produce a composite score ranging from 0 to 100, with a score below 20 serving as the primary efficacy benchmark in JAK inhibitor clinical trials.